ViiV HEALTHCARE ANNOUNCES COLLABORATION WITH RADBOUD UNIVERSITY MEDICAL CENTER IN THE NETHERLANDS TO IDENTIFY NEW DRUG TARGETS FOR HIV

Collaboration will process anonymised patient data, genetic information and environmental factors to better understand the biology associated with HIV and identify early targets for new medicines

London, UK, 26 February 2019 – ViiV Healthcare is announcing a five-year collaboration with Radboud university medical center (Radboudumc) in Nijmegen, The Netherlands, providing dedicated funding to enhance the HIV-specific capability of the Human Functional Genomics Project (HFGP). The HFGP is a large-scale project that combines detailed patient data with cross-omics information, host immune responses and environmental factors to better understand how the body recognizes and defends itself from disease as well as the signs, symptoms and progression of disease.

Under the supervision of a Scientific Management Board (SMB) comprising representatives from ViiV Healthcare and Radboudumc, Radboudumc will expand the cohort of HIV-infected individuals that are part of the HFGP from 200 to 2000 people. Data from this cohort will be used to look at the predictors and pathways of diseases that are specific to people living with HIV and how they might differ from other disease areas and from healthy people who do not have HIV. Using that information, the goal is to identify early stage drug targets that ViiV Healthcare could use to develop new medicines or approaches to treat HIV infection.

The project, called “HIV 2000+” will be the first comprehensive cohort study in HIV to use a field of biology called “cross-omics,” which uses genomics, microbiome metagenomics, and metabolomics technologies to better understand the underlying biology associated with HIV infection.

Jan van Lunzen, MD PhD, Head of Translational Medical Research at ViiV Healthcare and project coordinator said: “This project will enable us to establish one of the best characterized cohorts of people living with HIV in the world and will not only help to better define biomarkers and pathways of disease progression, but may also serve as a fantastic platform to find new drug targets.”

The collaboration will combine Radboudumc’s experience in infectious diseases, established networks and scientific techniques with ViiV Healthcare’s expertise and innovation in discovering and developing medicines for HIV.

Mihai Netea, MD PhD, Professor and Head of the Division of Experimental Internal Medicine at Radboud university medical center said: “This is a unique collaboration which will combine for the first time in-depth clinical and pathophysiological phenotyping with a systems biology approach in a large population of patients with HIV. It is a unique chance to understand better the HIV infection and its complications, and to partner with ViiV Healthcare to translate that knowledge to the bed of the patient.”

Deal terms
ViiV Healthcare will fully fund the five-year collaboration that will analyse cross-omics data from 2,000 HIV-infected patients and compare the data to that from other diseases areas and from healthy volunteers.  Scientists from both Radboudumc and ViiV Healthcare will collaborate closely on the work packages that will be formed as part of the collaboration.

An SMB comprising members from both Radboudumc and ViiV Healthcare will provide both scientific and financial oversight of the collaboration and an Independent Scientific Advisory Board will also be formed to advise the SMB.   

About ViiV Healthcare
ViiV Healthcare is a global specialist HIV company established in November 2009 by GlaxoSmithKline (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in treatment and care for people living with HIV and for people who are at risk of becoming infected with HIV. Shionogi joined as a shareholder in October 2012. The company’s aim is to take a deeper and broader interest in HIV/AIDS than any company has done before and take a new approach to deliver effective and innovative medicines for HIV treatment and prevention, as well as support communities affected by HIV.

For more information on the company, its management, portfolio, pipeline, and commitment, please visit www.viivhealthcare.com.

About Radboud university medical center

Radboud university medical center is an institute for patient care, research and education and training, located in Nijmegen, The Netherlands. Our mission is to have a significant impact on healthcare. We aim to be a frontrunner in the development of innovative, sustainable and affordable healthcare. By offering excellent quality, participatory and personalised healthcare, operational excellence and sustainable networks. Our almost 10,000 employees and over 3,000 students do their utmost every day to make a positive contribution to the future of healthcare and medical sciences. https://www.radboudumc.nl/en/research

About the Human Functional Genomics Project

The Human Functional Genomics Project is an international collaboration coordinated by scientists from the Department of Internal Medicine, Radboudumc, which aims to identify the factors that influence the immune responses during health and disease on the one hand, and the susceptibility, severity and complications of immune-mediated diseases on the other hand.

http://www.humanfunctionalgenomics.org/site/

 

ViiV Healthcare Media enquiries:

Melinda Stubbee

+1 919 491 0831

 

Audrey Abernathy

+1 919 605 4521

Radboudumc Media enquiries:

Anne van Kessel

+31 (0) 24 361 8910